D220
DKFZ -Bayer Healthcare Joint
Also known as:D220; DKFZ-Bayer Healthcare Joint Immunotherapeutics Laboratory; Immuntherapie Labor
ID | I:(DE-He78)D220-20160331 |
Recent Publications
All known publications ...
Download: BibTeX | EndNote XML, Text | RIS |
http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Journal Article
Mowat, J. ; Carretero, R.DKFZ* ; Leder, G. ; Aiguabella Font, N. ; Neuhaus, R.DKFZ* ; Berndt, S. ; Günther, J. ; Friberg, A. ; Schäfer, M. ; Briem, H. ; Raschke, M. ; Miyatake Ondozabal, H. ; Buchmann, B. ; Boemer, U. ; Kreft, B. ; Hartung, I. V. ; Offringa, R. (Last author)DKFZ*
Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer
Journal of medicinal chemistry 67(19), 17429-17453 (2024) [10.1021/acs.jmedchem.4c01325]2024
Files
BibTeX |
EndNote:
XML,
Text |
RIS
http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Journal Article
Li, Z.-J. ; He, B. ; Domenichini, A. ; Satiaputra, J. ; Wood, K. H. ; Lakhiani, D. D. ; Bashaw, A. A. ; Nilsson, L. M. ; Li, J. ; Bastow, E. R. ; Johansson-Percival, A. ; Denisenko, E. ; Forrest, A. R. ; Sakaram, S. ; Carretero, R.DKFZ* ; Hämmerling, G. J.DKFZ* ; Nilsson, J. A. ; Lee, G. Y. ; Ganss, R.
Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models.
The journal of clinical investigation 134(18), e179860 (2024) [10.1172/JCI179860]2024
BibTeX |
EndNote:
XML,
Text |
RIS
http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Journal Article
Kilian, M. (First author)DKFZ* ; Sheinin, R. ; Tan, C. L.DKFZ* ; Friedrich, M.DKFZ* ; Krämer, C.DKFZ* ; Kaminitz, A. ; Sanghvi, K.DKFZ* ; Lindner, K.DKFZ* ; Chih, Y.-C.DKFZ* ; Cichon, F.DKFZ* ; Richter, B.DKFZ* ; Jung, S.DKFZ* ; Jähne, K.DKFZ* ; Ratliff, M. ; Prins, R. M. ; Etminan, N. ; von Deimling, A.DKFZ* ; Wick, W.DKFZ* ; Madi, A. ; Bunse, L. (Last author)DKFZ* ; Platten, M. (Last author)DKFZ*
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.
Cancer cell 41(2), 235-251.e9 (2023) [10.1016/j.ccell.2022.12.007]2023
BibTeX |
EndNote:
XML,
Text |
RIS
http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Journal Article
Kober, C. (First author)DKFZ* ; Roewe, J.DKFZ* ; Schmees, N. ; Roese, L. ; Roehn, U. ; Bader, B. ; Stoeckigt, D. ; Prinz, F. ; Gorjánácz, M. ; Roider, H. G. ; Olesch, C.DKFZ* ; Leder, G. ; Irlbacher, H. ; Lesche, R. ; Lefranc, J. ; Oezcan-Wahlbrink, M.DKFZ* ; Batra, A. S.DKFZ* ; Elmadany, N.DKFZ* ; Carretero, R.DKFZ* ; Sahm, K.DKFZ* ; Oezen, I.DKFZ* ; Cichon, F.DKFZ* ; Baumann, D.DKFZ* ; Sadik, A.DKFZ* ; Opitz, C. A.DKFZ* ; Weinmann, H. ; Hartung, I. V. ; Kreft, B. ; Offringa, R.DKFZ* ; Platten, M.DKFZ* ; Gutcher, I.
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.
Journal for ImmunoTherapy of Cancer 11(11), e007495 (2023) [10.1136/jitc-2023-007495]2023
BibTeX |
EndNote:
XML,
Text |
RIS
http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Journal Article (Letter)
Steinfass, T. (First author)DKFZ* ; Poelchen, J.DKFZ* ; Sun, Q.DKFZ* ; Mastrogiulio, G.DKFZ* ; Novak, D.DKFZ* ; Vierthaler, M. ; Pardo, S.DKFZ* ; Federico, A.DKFZ* ; Hüser, L.DKFZ* ; Hielscher, T.DKFZ* ; Carretero, R.DKFZ* ; Offringa, R.DKFZ* ; Altevogt, P.DKFZ* ; Umansky, V.DKFZ* ; Utikal, J. (Last author)DKFZ*
Secretogranin II influences the assembly and function of MHC class I in melanoma.
Experimental hematology & oncology 12(1), 29 (2023) [DOI: 10.1186/s40164-023-00387-1]2023
Fulltext by Pubmed Central
BibTeX |
EndNote:
XML,
Text |
RIS
http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Journal Article
Weisshaar, N. (First author)DKFZ* ; Wu, J.DKFZ* ; Ming, Y.DKFZ* ; Madi, A. A. M.DKFZ* ; Hotz-Wagenblatt, A.DKFZ* ; Ma, S.DKFZ* ; Mieg, A.DKFZ* ; Hering, M.DKFZ* ; Zettl, F.DKFZ* ; Mohr, K.DKFZ* ; Schlimbach, T.DKFZ* ; Ten Bosch, N.DKFZ* ; Hertel, F.DKFZ* ; Müller, L.DKFZ* ; Byren, H.DKFZ* ; Wang, M.DKFZ* ; Borgers, H.DKFZ* ; Munz, M.DKFZ* ; Schmitt, L.DKFZ* ; van der Hoeven, F.DKFZ* ; Kloz, U.DKFZ* ; Carretero, R.DKFZ* ; Schleußner, N.DKFZ* ; Jackstadt, R.-F.DKFZ* ; Hofmann, I.DKFZ* ; Cui, G. (Last author)DKFZ*
Rgs16 promotes antitumor CD8+ T cell exhaustion.
Science immunology 7(71), eabh1873 (2022) [10.1126/sciimmunol.abh1873]2022
BibTeX |
EndNote:
XML,
Text |
RIS
http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Journal Article (Review Article)
Olesch, C. (First author)DKFZ* ; Brüne, B.DKFZ* ; Weigert, A.DKFZ*
Keep a Little Fire Burning—The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity
International journal of molecular sciences 23(3), 1289 (2022) [10.3390/ijms23031289]2022
BibTeX |
EndNote:
XML,
Text |
RIS
http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Journal Article
Pinkert, J. (First author)DKFZ* ; Boehm, H.-H.DKFZ* ; Trautwein, M. ; Doecke, W.-D. ; Wessel, F.DKFZ* ; Ge, Y.DKFZ* ; Gutierrez, E. M.DKFZ* ; Carretero, R.DKFZ* ; Freiberg, C. ; Gritzan, U. ; Luetke-Eversloh, M. ; Golfier, S. ; Von Ahsen, O. ; Volpin, V. ; Sorrentino, A. ; Rathinasamy, A. ; Xydia, M. ; Lohmayer, R. ; Sax, J. ; Nur-Menevse, A. ; Hussein, A. ; Stamova, S. ; Beckmann, G. ; Glueck, J. M. ; Schoenfeld, D. ; Weiske, J. ; Zopf, D. ; Offringa, R.DKFZ* ; Kreft, B. ; Beckhove, P.DKFZ* ; Willuda, J.
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction
OncoImmunology 11(1), 2008110 (2022) [10.1080/2162402X.2021.2008110]2022
BibTeX |
EndNote:
XML,
Text |
RIS
http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Journal Article
Baumann, D. (First author)DKFZ* ; Hägele, T.DKFZ* ; Mochayedi, J.DKFZ* ; Drebant, J.DKFZ* ; Vent, C.DKFZ* ; Blobner, S.DKFZ* ; Noll, J. H.DKFZ* ; Nickel, I.DKFZ* ; Schumacher, C.DKFZ* ; Boos, S. L.DKFZ* ; Daniel, A. S.DKFZ* ; Wendler, S.DKFZ* ; Volkmar, M.DKFZ* ; Strobel, O. ; Offringa, R. (Last author)DKFZ*
Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy.
Nature Communications 11(1), 2176 (2020) [10.1038/s41467-020-15979-2]2020
BibTeX |
EndNote:
XML,
Text |
RIS
http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Journal Article
Bode, K. (First author)DKFZ* ; Bujupi-Osmani, F.DKFZ* ; Link, C.DKFZ* ; Hein, T.DKFZ* ; Zimmermann, S. ; Peiris, D. ; Jaquet, V. ; Lepenies ; Weyd, H.DKFZ* ; Krammer, P. (Last author)DKFZ*
Dectin-1 binding to annexins on apoptotic cells induces peripheral immune tolerance via NADPH oxidase-2.
Cell reports 29(13), 4435-4446.e9 (2019)2019
BibTeX |
EndNote:
XML,
Text |
RIS
All known publications ...
Download: BibTeX | EndNote XML, Text | RIS |